Stockreport

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythe...

Protagonist Therapeutics, Inc.  (PTGX) 
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com
PDF Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivo [Read more]